Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Kelli A Monaco"'
Autor:
Anupama Reddy, Joseph D Growney, Nick S Wilson, Caroline M Emery, Jennifer A Johnson, Rebecca Ward, Kelli A Monaco, Joshua Korn, John E Monahan, Mark D Stump, Felipa A Mapa, Christopher J Wilson, Janine Steiger, Jebediah Ledell, Richard J Rickles, Vic E Myer, Seth A Ettenberg, Robert Schlegel, William R Sellers, Heather A Huet, Joseph Lehár
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146635 (2016)
Externí odkaz:
https://doaj.org/article/59c3f93f2d5c4482aef340a64a791f66
Autor:
Anupama Reddy, Joseph D Growney, Nick S Wilson, Caroline M Emery, Jennifer A Johnson, Rebecca Ward, Kelli A Monaco, Joshua Korn, John E Monahan, Mark D Stump, Felipa A Mapa, Christopher J Wilson, Janine Steiger, Jebediah Ledell, Richard J Rickles, Vic E Myer, Seth A Ettenberg, Robert Schlegel, William R Sellers, Heather A Huet, Joseph Lehár
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138486 (2015)
Death Receptor 5 (DR5) agonists demonstrate anti-tumor activity in preclinical models but have yet to demonstrate robust clinical responses. A key limitation may be the lack of patient selection strategies to identify those most likely to respond to
Externí odkaz:
https://doaj.org/article/65b59ba5d911495fa33f7b9acb527174
Autor:
Giordano Caponigro, Vesselina G. Cooke, Darrin D. Stuart, Jeffrey A. Engelman, Peter S. Hammerman, Stephania Widger, Gwynn Pardee, Kenneth Crawford, John Fuller, Mariela Jaskelioff, Lesley Griner, Felipa Mapa, Jessi Ambrose, Peter Aspesi, John Green, Karen Bui, Jinsheng Liang, Hui Qin Wang, Stacy Higgins, Ribo Guo, Daniel McKay, Emma Labrot, Paul Fordjour, Yuji Mishina, Jing Yuan, Scott Delach, Kelli-Ann Monaco
Supplementary Figure 4. Growth of individual tumors shown in Fig. 7A-C are given for HCT 116 (A), MIA PaCa-2 (B) and MEL-JUSO (C) cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2175679541bcf9cea1bfe131eae3dc26
https://doi.org/10.1158/1078-0432.22480680
https://doi.org/10.1158/1078-0432.22480680
Autor:
Giordano Caponigro, Vesselina G. Cooke, Darrin D. Stuart, Jeffrey A. Engelman, Peter S. Hammerman, Stephania Widger, Gwynn Pardee, Kenneth Crawford, John Fuller, Mariela Jaskelioff, Lesley Griner, Felipa Mapa, Jessi Ambrose, Peter Aspesi, John Green, Karen Bui, Jinsheng Liang, Hui Qin Wang, Stacy Higgins, Ribo Guo, Daniel McKay, Emma Labrot, Paul Fordjour, Yuji Mishina, Jing Yuan, Scott Delach, Kelli-Ann Monaco
p-ERK MSD results in RAS mutant cells ectopically expressed ARAF variants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a06d1625834f006100db5b3daf5cfda
https://doi.org/10.1158/1078-0432.22480659
https://doi.org/10.1158/1078-0432.22480659
Autor:
Giordano Caponigro, Vesselina G. Cooke, Darrin D. Stuart, Jeffrey A. Engelman, Peter S. Hammerman, Stephania Widger, Gwynn Pardee, Kenneth Crawford, John Fuller, Mariela Jaskelioff, Lesley Griner, Felipa Mapa, Jessi Ambrose, Peter Aspesi, John Green, Karen Bui, Jinsheng Liang, Hui Qin Wang, Stacy Higgins, Ribo Guo, Daniel McKay, Emma Labrot, Paul Fordjour, Yuji Mishina, Jing Yuan, Scott Delach, Kelli-Ann Monaco
Purpose:Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254.Experimental Design:LXH254 was profiled in biochemical, in vitro, and in vivo assays,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d1b1fef6c36ab7ea76ff43f5c11d34
https://doi.org/10.1158/1078-0432.c.6530499.v1
https://doi.org/10.1158/1078-0432.c.6530499.v1
Autor:
Giordano Caponigro, Vesselina G. Cooke, Darrin D. Stuart, Jeffrey A. Engelman, Peter S. Hammerman, Stephania Widger, Gwynn Pardee, Kenneth Crawford, John Fuller, Mariela Jaskelioff, Lesley Griner, Felipa Mapa, Jessi Ambrose, Peter Aspesi, John Green, Karen Bui, Jinsheng Liang, Hui Qin Wang, Stacy Higgins, Ribo Guo, Daniel McKay, Emma Labrot, Paul Fordjour, Yuji Mishina, Jing Yuan, Scott Delach, Kelli-Ann Monaco
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::703cf919309a8d21ff2ef43d79a39ca5
https://doi.org/10.1158/1078-0432.22480674.v1
https://doi.org/10.1158/1078-0432.22480674.v1
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Autor:
Jacob R. Haling, David A. Ruddy, Giordano Caponigro, Jodi Meltzer, Scott Delach, Daniel P. Rakiec, Marissa Balak, Michael G. Acker, Joshua M. Korn, Ping Wang, Kelli-Ann Monaco, Caroline Emery, Alyson K. Freeman
Publikováno v:
Molecular Cancer Research. 15:1431-1444
Alterations in MEK1/2 occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in BRAF-V600E–mutant melanoma and colorectal cancer. Efforts were undertaken to understand the effects
Autor:
Paul Fordjour, Giordano Caponigro, Kelli-Ann Monaco, Mariela Jaskelioff, Scott Delach, Yun Feng, Darrin Stuart, Salonee Parikh
Publikováno v:
Cancer Research. 79:LB-114
RAS mutant tumors have proven largely refractory to inhibitors of the MAPK pathway in clinic. In contrast, selective inhibitors of BRAFV600E but not wild type RAF have been successfully developed in BRAFV600E mutant melanoma, NSCLC, and thyroid cance
Autor:
Victoria L. Bautch, Rebecca Rapoport, Natalie Johnson, Carrie A. Ambler, Kelli Ann Monaco, Joseph B. Kearney
Publikováno v:
Blood. 99:2397-2407
Mice lacking the vascular endothelial growth factor (VEGF) receptor flt-1 die of vascular overgrowth, and we are interested in how flt-1 normally prevents this outcome. Our results support a model whereby aberrant endothelial cell division is the cel